August 03, 2022 HERCULES, Calif.–(BUSINESS WIRE)– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland,... Read more
July 27, 2021 at 6:30 AM EDTPDF Version Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes PLEASANTON, Calif., July 27, 2021 (GLOBE NEWSWIRE) — 10x Genomics, Inc. (Nasdaq: TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb). The... Read more
Date: 04/21/2020 HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the commercial launch of its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-CoV-2, the virus associated with COVID-19 disease. Bio-Rad has... Read more
HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The outlook was changed to stable from positive. According to Moody’s, the upgrade reflects recent... Read more
Date: 04/22/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. In this role, Dr. Last is responsible for all operating functions of the company... Read more
Date: 04/02/2019 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease. Lyme... Read more
Date: 12/03/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced expanded global access of the company’s quality controls across multiple Abbott clinical diagnostics platforms that now includes the Abbott Alinity ci-series instruments. “We are pleased to fulfill this need and offer customers... Read more
Date: 11/13/2018 HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company has been awarded a contract for iQ-Check real-time PCR pathogen detection test kits and the iQ-Check Prep Automation System from the United States Department of Agriculture’s Food Safety and... Read more
Date: 03/22/2018 HERCULES, Calif. — March 22, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE’s continued... Read more
HERCULES, Calif. — January 22, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad’s IH-System... Read more